Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Antimicrobial Agents and Chemotherapy|October 28, 2009
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantationV Kohl, C Müller, O A Cornely, et al.
Bone Marrow Transplantation|June 26, 1999
Using at least 5x10(6)/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantationC Scheid, A Draube, M Reiser, et al.
Bone Marrow Transplantation|July 22, 1999
Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilizationM Reiser, A Josting, A Draube, et al.
The Journal of Urology|March 1, 1996
Oxalate toxicity in LLC-PK1 cells, a line of renal epithelial cellsC Scheid, H Koul, W A Hill, et al.
Bone Marrow Transplantation|March 31, 2026
IPSS-M downstaging before transplantation does not improve the prognosis of patients with myelodysplastic neoplasmsT Richardson, D Schütte, P Gödel, et al.
European Journal of Haematology|November 13, 2024
Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma-A Retrospective Multicenter AnalysisT Richardson, G Kobbe, R Fenk, et al.
The Journal of Family Practice|December 1, 1993
Does family practice at residency teaching sites reflect community practice?V Gilchrist, R S Miller, W R Gillanders, et al.
Bone Marrow Transplantation|November 14, 2017
Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantationF Farowski, V Bücker, J J Vehreschild, et al.
Annals of Hematology|August 12, 2015
Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality--a single institution experienceG Chakupurakal, S Leitzke, P Langerbeins, et al.
Bone Marrow Transplantation|March 2, 2011
Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USAK W Douglas, A N Parker, P J Hayden, et al.
Pageof 9